Shares of Claritev Corporation (CTEV) soared 5.28% in Wednesday's intraday trading session following the release of the company's third quarter 2025 financial results and business update. The biotechnology firm, which specializes in developing universally implantable bioengineered human tissues, reported significant progress in both its commercial and clinical endeavors.

Claritev announced total revenues of $753,000 for the third quarter, with $703,000 coming from U.S. sales of its FDA-approved Symvess product for vascular trauma. This marks a substantial increase from $100,000 in sales during the second quarter, reflecting growing market acceptance and increased hospital approvals. The company has secured 25 Value Analysis Committee (VAC) approvals, making Symvess eligible for purchase in 92 civilian hospitals.

Beyond its commercial success, Claritev reported advancements in its clinical pipeline. The company is progressing toward a planned supplemental Biologics License Application (BLA) filing for its acellular tissue engineered vessel (ATEV) in dialysis access. Additionally, Claritev has submitted an Investigational New Drug (IND) application to the FDA for its coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG), with plans to advance to first-in-human studies in 2026. These developments, coupled with positive clinical data presentations and publications, have bolstered investor confidence in the company's growth potential.